Article Text

AB0455 Dyslipidemia and Atherogenic Risk in Patients with Systemic Lupus Erythematosus
  1. H.A. Radillo1,
  2. J.A. Batún1,
  3. E. Hernández2
  1. 1Internal Medicine
  2. 2Hospital de Alta Especialidad Dr. Gustavo A. Rovirosa Pérez, Villahermosa, Mexico


Background Dyslipidemia is a common comorbidity in patients with systemic lupus erythematosus, it is favored by central obesity, nephrotic syndrome, glucocorticoids and immunosuppressants.

Methods 51 patients, who were determined the lipid profile were included. Variables associated with the disease and the drugs used were recorded. Atherogenic risk was calculated. Chi square was used for categorical variables. ANOVA was performed to determine the relationship between mean lipid profile and a logistic regression model to determine the association of the variables with the presence of dyslipidemia.

Results 68.6% had dyslipidemia. Significant difference between the presence of dyslipidemia and Activity index measured by SLEDAI (p=0.021) was found, the presence of lupus nephritis (P=0.021), use of prednisone ≥20 mg/day (p=0.0009), evolution disease <3 years (P=0.027). Significance between the absence of dyslipidemia and use of hydroxychloroquine (P=0.021) was found. Activity index ≥4 (RR 6.34; p=0.038) and the use of prednisone >20 mg/day (RR 6.67; p=0.036) were independently associated with the presence of dyslipidemia. The average of Castelli rate was 5.02±1.8, the Kannel index was 2.97±1.4 and triglyceride/HDL-C ratio was 5.24 ±3.3.

Conclusions Patients with systemic lupus erythematosus have a high prevalence of dyslipidemia and a high atherogenic rate, which increases cardiovascular risk significantly.

  1. Olusi S, George S. Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. Vasc Health Risk Manag. 2011; 7: 75–80.

  2. Aguilar C, Gόmez F, Lerman I, Vázquez C, Pérez O, Posadas C. Diagnόstico y tratamiento de las dislipidemias. Revista de Endocrinología y Nutriciόn. 2004; 12 (1); 7–41.

  3. Graham I, Cooney M, Bradley D, Dudina A, Reiner Z. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep. 2012; 14 (6): 709–20.

  4. Manzi S, Meilahn E, Rairie J, Conte C, Medsger T, Jansen L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study. Am J Epidemiol. 1997; 145: 408–15.

  5. Amaya J, Sarmiento J, Caro J, Molano N, Mantilla R, Rojas A et al. Caridiovascular disease in Latin American patients with systemic lupus erythematosus: A cross sectional study and a systematic review. Autoimmune Diseases. 2013; 1: 1–20.

  6. Galindo J, Natividad J, Orellano C, Calvo A, Berrocal A. Dislipidemia en pacientes con artritis reumatoide atendidos en un hospital general. Rev Med Hered. 2011; 22: 47–53.

  7. - Trevisan R, Dodesini A, Lepore G. Lipids and renal disease. J Am Soc Nephrol. 2006; 17 (4): 145–7

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.